医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Frontage Doubles Bioanalytical Lab Capacity in USA Due to Increased Demand for Services

2015年09月29日 PM10:45
このエントリーをはてなブックマークに追加


 

EXTON, Pa.

Frontage, a full service contract research organization (CRO) located in the USA and China, is pleased to announce the expansion of its bioanalytical laboratories to meet increased demand for its services from existing and new biopharmaceutical clients.

As one of the leading providers of bioanalytical services for small molecules, large molecules and biologics, including the bioanalysis of Antibody Drug Conjugates (ADCs) by Mass Spectroscopy and Ligand Binding platforms, Frontage has completed an expansion of their Exton, PA operations. With an additional 10,000 square feet of laboratories, this expansion allows for the installation of 20 additional state-of-the-art mass spectrometers, including the SCIEX TripleTOF® 6600 System for the measurement of peptides, antibodies and ADCs, and four (4) SCIEX Triple Quad™ 6500 Systems, bringing the number of MS systems to more than 50 globally. Frontage’s expansion increases the site’s deep freezer capacity to thirty-two (32) -70 °C freezers, equipped with emergency backup power generation. The company also added laboratories that expand its Biologics service offerings for ECL and ELISA-based assays, as well as its growing DMPK operations supporting discovery-stage pharmacokinetics and development-stage metabolism studies.

Frontage has complemented the facility expansion with the hiring of 21 additional, highly-talented scientific personnel, including eight (8) Ph.D. chemists. With new equipment, lab space and scientific team members, Frontage is continuing its efforts to improve client satisfaction and turn-around times for method development, validation and analysis of regulated bioanalytical samples with an increased capacity of 50,000 samples per month.

“Frontage’s expansion of our bioanalytical and DMPK operations is an essential step of meeting our client’s expectations to provide high quality services efficiently and economically. It is very exciting to see our company grow to meet these demands and have the ability to add some great people to our teams. We have also invested in equipment that will allow us to remain at the forefront of drug development and enable us to analyze increasingly complex new drug candidates. We are thankful for all of the clients that have put their trust in Frontage and for our team members who continue to perform at a high level,” said Dr. Song Li, CEO of Frontage.

About Frontage

Frontage is a full service CRO assisting biopharmaceutical organizations in their research and product development efforts. Spanning from the discovery stages through late-stage clinical trials, our full service offerings include bioanalysis using more than 50 LC-MS/MS instruments, preclinical and clinical studies, analytical testing, product development support, DMPK and biometrics. Our company also provides turnkey product development, bioequivalence and analytical services to generic and consumer health pharmaceutical companies to support ANDA, and 505(b)(2) new drug application submissions.

Founded in 2002, the business has grown to state-of-the art research facilities in the US and China. Our experienced teams provide study management services for all phases of clinical research, including monitoring, data management, biostatistics and medical writing.

Frontage has enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development to commercial launch in global markets. For more information, visit www.frontagelab.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150929006186/en/

CONTACT

Frontage Laboratories, Inc.
Meredith Faragalli, Marketing
484-348-4813
mfaragalli@frontagelab.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 企業と政治のリーダーがバイデン大統領宛の書簡に署名し、米国のリーダーシップで世界的なワクチン接種への取り組みを加速させるよう要請
  • 美国政商领袖签署致拜登总统公开信,呼吁美国展现领导力以加速全球疫苗接种工作
  • Ferring和Rebiotix将在2021消化疾病周大会上公布基于微生物群的在研活体生物治疗药物RBX2660的里程碑数据
  • アスターDMヘルスケア、25万米ドル相当の世界看護賞を発表
  • Prestige BioPharma Enters MOU with Busan City for Establishment of its R&D Centre in Busan, South Korea